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Abstract
Background/Aims
Animal tuberculosis (TB) is a complex animal health problem that causes disruption to trade
and significant economic losses. TB involves a multi-host system where sheep, traditionally
considered a rare host of this infection, have been recently included. The aims of this study
were to develop an experimental TB infection model in sheep with a Mycobacterium caprae
field strain isolated from a tuberculous diseased ewe, and to use this to evaluate the safety
and efficacy of two vaccines against TB in sheep, the live-attenuated M. bovis BCG vaccine
(Danish strain) and a heat-inactivated M. bovis (HIMB) vaccine.
Methods
Eighteen 2 month-old lambs were experimentally challenged with M. caprae by the endotra-
cheal route (1.5 × 103 CFU). They were separated per treatment group into parenterally vac-
cinated with a live BCG Danish strain vaccine (n = 6), orally vaccinated with a suspension of
HIMB (n = 6) and unvaccinated controls (n = 6). Clinical, immunological, pathological and
bacteriological parameters of infection were measured.
Results
All lambs were successfully infected and developed gross TB lesions in the respiratory sys-
tem. The BCG vaccine conferred considerable protection against experimental TB in lambs,
PLOS ONE | https://doi.org/10.1371/journal.pone.0180546 July 5, 2017 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Balseiro A, Altuzarra R, Vidal E, Moll X,
Espada Y, Sevilla IA, et al. (2017) Assessment of
BCG and inactivated Mycobacterium bovis
vaccines in an experimental tuberculosis infection
model in sheep. PLoS ONE 12(7): e0180546.
https://doi.org/10.1371/journal.pone.0180546
Editor: Pere-Joan Cardona, Fundacio´ Institut
d’Investigacio´ en Ciències de la Salut Germans
Trias i Pujol, Universitat Autònoma de Barcelona,
SPAIN
Received: February 3, 2017
Accepted: June 16, 2017
Published: July 5, 2017
Copyright: © 2017 Balseiro et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was funded by a grant from
Instituto Nacional de Investigacio´n y Tecnologı´a
Agraria y Alimentaria (INIA), reference number
RTA2014-0002-C02-01 (FEDER co-funded). IRTA
is supported by CERCA Programme / Generalitat
de Catalunya.
as measured by a reduction of the gross lesion volumes and bacterial load. However, HIMB
vaccinated animals did not show protection.
Conclusions
This study proposes a reliable new experimental model for a better understanding of tuber-
culosis in sheep. BCG vaccination offers an effective prospect for controlling the disease.
Moreover alternative doses and/or routes of administration should be considered to evalu-
ate the efficacy of the HIMB vaccine candidate.
Introduction
Animal tuberculosis (TB) is a mycobacterial disease that affects a broad range of mammals
including domestic animals, wildlife and humans. It is caused by members of the Mycobacte-
rium tuberculosis complex (MTBC), most commonly Mycobacterium bovis and Mycobacterium
caprae [1]. It is one of the most complex animal health problems that the ungulate farming
industry faces today [2]. TB causes disruption to trade and significant economic losses [3]. In
Europe animal TB involves a multi-host system where domestic (cattle and goats) and wildlife
(badger, wild boar and red deer) have a relevant role that varies between regions, depending
on climate, habitat and husbandry factors [4]. Recent studies have shown that sheep, tradition-
ally considered a rare host for the MTBC, can be part of the multi-species system which may
maintain TB in a region, at least in mixed farms where sheep cohabit with TB-infected cattle
and/or goats [5]. Given the abundance and widespread distribution of domestic sheep in
Europe and elsewhere, that role may have important implications for global animal TB control,
particularly since sheep are not routinely subjected to the periodic diagnostic testing within
the National Programmes to eradicate bovine TB in many countries where TB is prevalent in
cattle or goats [5].
Vaccination against TB gains renewed interest when the strategy of test and cull fails in
achieving TB eradication. Nowadays, bacille Calmette-Gue´rin (BCG), a live attenuated strain
of M. bovis, is the only available vaccine against human TB and its efficacy and safety have
already been studied in several animal TB hosts, such as cattle, goats, badgers, brushtail pos-
sums, wild boar, white-tailed deer and African buffalo [6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16].
However, the use of BCG vaccination against M. bovis in cattle is explicitly forbidden by EU
legislation. The rationale is the lack of availability of diagnostic tests to differentiate vaccinated
from infected animals (DIVA tests) [2]. In countries where test and cull control strategies are
ongoing, DIVA tests would be necessary if, vaccination with BCG or other mycobacterial
based vaccines were applied [17]. Moreover, regarding wildlife oral vaccination, the safety of
baits on non-target species must be also considered [2]. Thus, a promising strategy is the use
of new inactivated oral vaccine candidates that display protection against TB and would also
have the advantages of being environmentally more stable and safe under field conditions and
of minimizing cross-reactions in diagnostic tests [18].
The aims of this study were (i) to develop an experimental TB infection model in sheep
with a M. caprae field strain isolated from a tuberculous diseased ewe, and (ii) to use it to eval-
uate the efficacy of two vaccines against TB in sheep, a live BCG vaccine (Danish strain) and a
heat-inactivated M. bovis preparation.
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Material and methods
Animals and experimental design
Eighteen 2 month-old Lacaune male lambs obtained from a farm with no TB history were
selected on the basis of negative results to the Interferon Gamma (IFN-γ) assay (ID Screen1
Ruminant IFN-g, ID.vet, Grabels, France) and were housed on an experimental farm where
they were identified and either parenterally vaccinated with a live-attenuated M. bovis BCG
Danish 1331 strain vaccine (n = 6) or orally vaccinated with a suspension of heat-inactivated
M. bovis (HIMB) (n = 6). The remaining 6 animals were kept as unvaccinated controls. Six
weeks after vaccination lambs were moved and housed in biosafety level 3 containment facili-
ties for acclimatization for one week prior to experimental challenge with M. caprae, which
was performed at week 7.
Before and during the experimental infection the lambs were observed for clinical signs.
Rectal temperature and body weight were measured prior to challenge and weekly and every
two weeks after challenge, respectively. Blood samples were collected at weeks 0, 2, 4, 7, 9, 11,
13, 15, 17 and 19 of the experiment from the jugular vein in heparinized blood tubes. Sampling
procedures and the challenge method were approved by the Animal Research Ethics Commit-
tee of the Principado de Asturias, Spain (reference number PROAE 20/2015).
Preparation of M. bovis BCG vaccine
The M. bovis BCG inoculum was prepared as previously described [14]. Briefly, M. bovis BCG
Danish 1331 strain (ATCC, Ref. 35733™) was sub-cultured in Middlebrook 7H9 media (BD
Diagnostics, USA). The bacterial growth was processed and titered as described above. The
stock suspension was thawed and diluted to 106 colony forming units (CFU)/ml in sterile PBS.
A single dose of 0.5 ml of this suspension (5 × 105 CFU) was subcutaneously inoculated on the
right scapula.
Preparation of heat-inactivated M. bovis vaccine (HIMB)
The M. bovis strain used was first isolated from a naturally infected wild boar on Coletsos
medium [18]. The isolate was propagated in Middlebrook 7H9 broth enriched with Oleic acid-
Albumin-Dextrose-Catalase (OADC Enrichment; Difco, USA) for 2–3 weeks. Cells were har-
vested by centrifugation at 2,500 x g for 20 minutes and washed twice in PBS. Bacterial pellets
were suspended in PBS and declumped using a fine needle syringe. After adjusting the bacte-
rial concentration, serial dilutions of the suspension were plated to assess the number of CFU
per milliliter. Inactivation of bacteria was carried out in an airtight bottle submerged in a water
bath at 84–85˚C for 45 minutes. Oral doses consisted of 2 ml of the inactivated suspension
containing approximately 107 CFU/ml of heat-inactivated bacteria. Inactivation was con-
firmed by culturing ten doses of the suspension in Mycobacterial Growth Indicator Tubes
(MGIT; Becton Dickinson, USA) and ten in agar-solidified Middlebrook 7H9 plates. The oral
vaccine was administered using a 2 ml syringe at week 0 of the experiment.
M. caprae inoculum preparation
The M. caprae SB0157 (www.Mbovis.org) field strain used as inoculum was originally isolated
from a tuberculous sheep from Catalonia. The isolate was sub-cultured in Middlebrook 7H9
broth (BD Diagnostics, Sparks MD, USA) supplemented with 0.5% (v/v) Tween 80, 40 mM
sodium pyruvate (Sigma-Aldrich, Steinheim, Germany) and 10% (v/v) albumin dextrose cata-
lase enrichment (BD Diagnostics, USA) at 37˚C for 21 days. The culture was centrifuged at
2500 rpm for 20 minutes and suspended in 2 ml of phosphate-buffered saline (PBS; Sigma-
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Aldrich, Steinheim, Germany) with 0.05% Tween 80 (PBS-T80). Two 1 ml aliquots of this
stock suspension were stored at -70˚C. Then an aliquot of the stock suspension was thawed
and titered by plating 100μl ten-fold serial dilutions in 7H11 solid media (BD Diagnostics,
USA). Plates were incubated at 37˚C and CFU were counted after 28 days. The inoculum was
prepared using the other aliquot at the required final suspension of 1.5 × 103 CFU of M. caprae
by diluting the stock suspension with PBS.
Experimental challenge
For infection at week 7, lambs were first sedated with 0.05 mg/kg of acepromazine maleate
(Equipromacina1) and 0.2 mg/kg of butorphanol tartrate (Torbugesic1) co-administered by
intramuscular injection. Approximately 30 minutes later, lambs were anesthetized with 4–6
mg/kg of propophol (Propofol Lipuro1) and 0.2 mg/kg of midazolam (Dormicum1) adminis-
tered intravenously. Afterwards, lambs were intubated with a sterilized endotracheal tube and
were placed in right lateral decubitus. A plastic cannula (3.3 mm outer diameter) was passed
through the endotracheal tube to the level of the carina. For inoculation, a thinner cannula
(2.1 mm outer diameter) was passed through the thicker one to a bronchus, and then 0.5 ml of
M. caprae inoculum was injected into the inner cannula, followed by flushing with 1 ml of
0.9% saline. The lambs recovered from anesthesia in sternal decubitus.
Antigens and peptides
Bovine purified protein derivative M. bovis (PPD-B) and M. avium (PPD-A) tuberculins were
obtained from CZ Veterinaria (Porriño, Galicia, Spain). Recombinant proteins ESAT-6, CFP-
10 and MPB83 were obtained from Lionex (Braunschweig, Germany). Peptide cocktails Prio-
nics™ PC-HP (based on ESAT-6, CFP-10 and 4 additional mycobacterial antigens) and Prio-
nics™ PC-EC (based on ESAT-6 and CFP-10) were supplied by Thermo Fisher Scientific
(Schlieren, Switzerland). Pokeweed mitogen (PWM) was obtained from Sigma-Aldrich.
Skin tests
Single intradermal tuberculin (SIT) and comparative intradermal tuberculin (CIT) tests were
carried out on all lambs at 10 weeks post-challenge (p.c.) (week 17 of the experiment) by inoc-
ulating 0.1 ml (2500 IU) of PPD-B and PPD-A on the right and the left side of the neck, respec-
tively. Skin-fold thickness was recorded just before inoculation and after 72 h. Qualitative
results were read according to the standard interpretation used in bovine TB eradication pro-
grams (Council Directive 64/432/EEC) [19]. Lambs were considered positive by SIT test when
clinical signs at the PPD-B inoculation site were observed or if the increase in skin-fold thick-
ness (SFT) at the PPD-B inoculation site was4 mm, and inconclusive if SFT was >2 mm and
<4 mm. Lambs were considered positive by CIT test when clinical signs at the PPD-B inocula-
tion site were observed or if the increase in SFT at the PPD-B inoculation site was>4 mm and
higher than the increase at the PPD-A inoculation site, and inconclusive when the SIT test was
positive or inconclusive and SFT at the PPD-B inoculation site was>1 mm and4 mm higher
than the increase at the PPD-A inoculation site.
Whole-blood IFN-γ assay
Blood samples were collected at the time points described above, preserved at room tempera-
ture, and processed less than 2 h after collection as described previously [16]. Briefly, one milli-
liter of whole blood was stimulated in 96-deepwell cell culture plates (Eppendorf Ibe´rica,
Madrid, Spain) with PPD-B, PPD-A (both used at a final concentration of 20 μg/ml), a mixture
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1:1 of recombinant proteins ESAT-6 and CFP-10 (E/C), used at a final concentration of 10 μg/
ml, and peptide cocktails PC-HP and PC-EC, used at weeks 0, 7, 9, 11, 13, 15 and 17 of the
experiment at the provider´s recommended concentration. Blood samples stimulated with
PWM (at a final concentration of 10 μg/ml) or PBS were used as positive and negative controls,
respectively. Samples were subsequently incubated at 37˚C overnight and ruminant IFN-γ
ELISA (ID Screen1 Ruminant IFN-g) was conducted from plasma supernatant following the
manufacturer instructions. The interpretation of qualitative results for the standard IFN-γ
assay (PPD-B and PPD-A) were performed according to manufacturer’s instructions.
Serology
Plasma samples from all animals were analyzed in duplicate for antibodies to MTBC using a
home-made ELISA [20]. 96-well plates were coated with the cell-surface lipoprotein MPB83
(0.5 g/ml) diluted in carbonate/bicarbonate buffer and incubated overnight at 4˚C. After
blocking for 45 minutes at 37˚C with PBS containing 0.05% Tween 20 (PBS-T20) with 0.5%
casein, plasma samples (at 1/200 dilution in PBS-T20 with 1% casein) were added in duplicate
and incubated for 1 hour at 37˚C. After washing, a combination of protein A and protein G
conjugated with peroxidase (Sigma-Aldrich, Steinheim, Germany) was added at final concen-
trations of 50 ng/ml and 100 ng/ml, respectively. The plates were then read in a spectropho-
tometer, and the OD450 was measured. A sample was classified as positive when the ΔOD450
(sample OD450 minus the blank wells OD450) was equal or higher than the optimal cut-off
point (ΔOD450 = 0.2) as previously determined [20].
Post-mortem examination
All lambs were euthanized at 12 weeks p.c. (week 19 of the experiment) by intravenous injec-
tion of sodium pentobarbital. At necropsy, lung gross lesions were recorded first by palpation
and external visual inspection was performed. Visible TB lesions found in other organs were
also recorded. Retropharyngeal (right and left), bronchial (right and left) and mediastinal (cra-
nial, medial and caudal) whole lymph nodes (LNs) were carefully removed without incising
the pleura and after this, lesion volumes were measured and processed for bacterial count. The
whole lungs (filled with formalin), submandibular and preescapular LNs were fixed with 10%
buffered formalin as previously described [21]. One month later the lungs were processed by
computed tomography (CT). To determine the volume of TB lesion in the LNs, the number
and diameter of macroscopic lesions were recorded and the approximate volumes of gross
lesions were calculated as the most likely 3D-geometrical morphology (namely, sphere, cylin-
der or prism). Submandibular and preescapular LNs were assessed by histopathology—hema-
toxylin and eosin and Ziehl-Neelsen (ZN) staining specific for acid-fast bacilli. Any other
tissue showing any TB compatible lesion was also submitted to histopathological analysis.
Computed tomography (CT)
After complete fixation, the lungs were scanned using a 16-slice multi-detector CT scanner
(Brivo CT-385, GE Healthcare, UK). Scanning parameters were: 120 kV, 122 mAs, with a large
sample field of view (SFOV: 43cm) and 0.6 mm slices using soft tissue and lung algorithms.
Sequential slices were analyzed and afterwards processed with the CT software allowing calcu-
lation of the volume. Tuberculous lesions were defined as any lesion in the lung parenchyma
with different density patterns: calcified lesions, cavitary lesions and solid lesions. The total
pulmonary volume, total volume of TB lesions and the total volume of the calcified lesions
were calculated for each lung. The total pulmonary volume was calculated with volume render-
ing (VR). To calculate the volume of the TB lesions 2D, 3D images, VR and multiplanar
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reconstructions were used and with segmentation tools they were isolated from the adjacent
parenchyma. Within the TB lesions, the calcified ones were selected by their Hounsfield Units
(range 100-400HU) and the total volume of them were calculated.
Bacterial count
Pulmonary and retropharyngeal LNs were homogenized in 10 ml of sterile distilled water in a
homogenizer (Masticator, IUL Instruments, Barcelona, Spain). The homogenate was decon-
taminated with a final concentration of 0.35% w/v hexadecylpyridinium chloride (HCP) for 15
minutes in orbital shaking and then centrifuged at 2471 × g for 30 minutes. The supernatant
was discarded and the pellet was suspended in 10 ml of PBS-T80. Homogenates were ten-fold
serially diluted in sterile PBS and 0.1 ml of each dilution was plated on Middlebrook 7H11
medium. The inoculated plates were incubated at 37˚C for 28 days. Afterwards, CFU enumer-
ation was performed and the total bacterial load in LNs was inferred. Colonies were confirmed
as MTBC by multiplex PCR [22].
Data analysis
Comparisons of rectal temperature, weight increase and bacterial load (Log10-transformed
counts) in LNs among the experimental groups were performed by one-way ANOVA with
Tukey test for pairwise comparisons. Differences in antigen-specific IFN-γ and IgG responses,
as well as differences in volumes of gross lesions among experimental groups, were compared
by non-parametric Kruskal-Wallis test with the post hoc Wilcoxon rank sum test. Correlations
between antigen-specific IFN-γ responses and post mortem parameters were assessed by non-
parametric Spearman’s rank correlation coefficient. Significance was set at p-value< 0.05. Sta-
tistical analysis was conducted with R package v2.15.0 (R Foundation for Statistical Comput-
ing, Vienna, Austria).
Results
Clinical signs and body condition
All animals were observed daily throughout the experiment and TB symptoms were not
detected. Rectal temperature was measured weekly p.c.
A peak of mean rectal temperature was observed on weeks 2–4 p.c in the control and HIMB
vaccinated groups (Fig 1). Rectal temperatures of lambs in the unvaccinated control group
were significantly higher (p< 0.05) than in the BCG vaccinated group on week 10 p.c. (Fig 1).
Rectal temperatures of lambs in the HIMB vaccinated group were significantly higher
(p< 0.05) than in the BCG vaccinated group from week 10 to 11 p.c. (Fig 1). From week 12
p.c. rectal temperatures remained below 39.5˚C, with no statistical differences between the
groups except for week 15 when the BCG vaccinated group presented a temperature signifi-
cantly higher (p< 0.05) than the HIMB vaccinated group.
In the BCG vaccinated group the mean body weight increase was significantly higher
(p< 0.05) than in the unvaccinated control animals at weeks 6 and 8 p.c. and in the HIMB vac-
cinated group at weeks 4, 6, 8 and 12 p.c. (Fig 2).
Immune responses following vaccination and challenge
The immunological response to vaccination and to infection with M. caprae was characterized
using both cell-mediated and humoral immunological tests. Table 1 shows the mean responses
per treatment group for SIT and CIT tests. All animals were positive by SIT and all except for
two (one BCG and one HIMB) to CIT at week 10 p.c.
Assessment of vaccines in an experimental TB infection model in sheep
PLOS ONE | https://doi.org/10.1371/journal.pone.0180546 July 5, 2017 6 / 16
Mean IFN- γ ex vivo response per treatment group for PPD-B and ESAT-6/CFP-10, PC-HP
and PC-EC cocktails is shown in Fig 3. The IFN- γ response to PPD-B started to rise in week 2
p.c. in the BCG group and was significantly higher in this group than in control and HIMB
groups (p< 0.01) at 2, 4 and 7 weeks of the experiment and significantly lower than the HIMB
group (p< 0.05) at 13 week of the experiment.
Fig 1. Rectal temperature after M. caprae challenge. Results are expressed as mean temperature (˚C) ±
95% confidence interval (CI) in unvaccinated control (n = 6), BCG vaccinated (n = 6) and HIMB vaccinated
(n = 6) lambs.
https://doi.org/10.1371/journal.pone.0180546.g001
Fig 2. Body weight increase of lambs after M. caprae challenge. Results are expressed as mean
cumulative weight (Kg) ± 95% CI in unvaccinated control (n = 6), BCG vaccinated (n = 6) and HIMB
vaccinated (n = 6) lambs.
https://doi.org/10.1371/journal.pone.0180546.g002
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Table 1. Results of the single intradermal tuberculin (SIT) and comparative intradermal tuberculin (CIT) tests. (+) Positive, (-) Negative, (I)
Inconclusive.
Group Id. Skin test (week 17, 10 weeks post-challenge)
0h 72h ΔPPD-B- ΔPPD-A Result
PPD-A PPD-B PPD-A PPD-B SIT CIT
Control 44 4.66 4.1 10.93 17.51 7.14 + +
45 3.61 3.49 6 10.7 4.82 + +
46 3.39 3.44 11.26 22.06 10.75 + +
48 3.19 3.25 6.95 11.47 4.46 + +
49 3.12 3.28 12.63 20.9 8.11 + +
66 3.71 3.55 8.87 13.1 4.39 + +
BCG 50 4.45 4.05 11.14 20.92 10.18 + +
51 3.95 3.3 7.52 13.54 6.67 + +
52 3.71 3.94 8.41 15.9 7.26 + +
56 3.48 3.81 7.75 14.09 6.01 + +
57 3.44 3.41 8.48 16.88 8.43 + +
61 3.53 3.66 8.43 9.06 0.5 + -
HIMB 53 3.05 3.11 9.88 14.55 4.61 + +
54 3.89 3.63 9.26 14.11 5.11 + +
55 3.62 3.6 7.61 12.66 5.07 + +
58 4.55 4.29 11.35 13.81 2.72 + I
59 3.22 3.02 6.65 19.42 12.97 + +
60 4.15 3.76 7.77 19.88 12.5 + +
https://doi.org/10.1371/journal.pone.0180546.t001
Fig 3. Whole blood antigen specific IFN-γ responses after vaccination and M. caprae challenge. The
graphic shows the determination of the IFN-γ release by ELISA (expressed as ΔOD450 ±CI) in plasma
supernatants after blood stimulation with (A) M. bovis PPD (PPD-B), (B) ESAT-6/CFP-10 recombinant
antigens mixture, (C) PC-HP cocktail and (D) PC-EC cocktail in unvaccinated control (n = 6), BCG vaccinated
(n = 6) and HIMB vaccinated (n = 6) lambs.
https://doi.org/10.1371/journal.pone.0180546.g003
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Levels of MPB83-specific IgG were measured as the antibody responses to M. caprae (Fig
4). The BCG group presented slightly higher IgG levels than the other two groups prior to chal-
lenge, which were significantly higher at week 7 of the experiment (p< 0.05). At 4 weeks p.c.
(week 11 of the study), 4 out of 6 control animals and 2 out of 6 HIMB vaccinated animals had
already seroconverted. At week 13 of the experiment (6 p.c.) a peak of IgG levels was observed
in the control group, significantly higher than in the HIMB vaccinated group (p< 0.05). At
this time point, 2 BCG vaccinated lambs were positive by the test. Two weeks after the CIT
test, levels of IgG rose in three groups and all animals were positive.
Pathology and bacteriology
All lambs presented gross TB lesions at necropsy exhibiting a wide range of sizes when com-
pared between groups. The volume of gross lesions in lungs, the ratio of the volume of lesions/
volume of lungs and the volume of calcification in lungs were measured using CT and are
shown in Table 2. The BCG vaccinated group showed a significant reduction (p< 0.01) of
gross lesions (mean volume of gross lesions and ratio of the volume of lesions/volume of
lungs, Table 2) in comparison with both the HIMB vaccinated and unvaccinated control
groups. A significant reduction in the volume of calcification was also observed in the BCG
vaccinated group (p< 0.05) compared to the other two groups. The total volume of TB lesions
using CT for each animal is shown in Fig 5.
The BCG vaccinated group showed a significantly lower mean volume of gross TB lesions
in pulmonary and retropharyngeal LNs (7.23 cm3, 95% CI: 0–15.64) compared to the HIMB
vaccinated group (32.64 cm3, 95% CI: 16.77–48.50; p< 0.05), and lower but not statistically
significant compared to the control group (21.79 cm3, 95% CI: 8.57–35.02; p> 0.05). BCG
Fig 4. Antibody responses to MPB83 after vaccination and M. caprae challenge. The graphic shows the
MPB83-specific IgG levels determined by ELISA (expressed as ΔOD450 ±CI) in unvaccinated control (n = 6),
BCG vaccinated (n = 6) and HIMB vaccinated (n = 6) lambs. The table on the horizontal axis shows the
qualitative results of the test (No. of seropositive/total lambs) for each group and time point.
https://doi.org/10.1371/journal.pone.0180546.g004
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vaccinated lambs showed a reduction of the total volume of visible lesions in lungs and respira-
tory LNs (p< 0.01) as well as a reduction of the total bacterial load in respiratory LNs
(p< 0.05) compared to the other groups (Fig 6).
TB lesions were mainly restricted to the respiratory system although extrapulmonary
lesions (generalization) in other LNs were also observed in some animals (see Table 3) and
Table 2. Pulmonary lesion assessment results for the three experimental groups analyzed by computed tomography (CT). The volume of lung
gross lesions, the ratio of the volume of lesions/volume of lungs, and the volume of calcification measured using computer tomography. Number of animals
showing cavitary lesions is also shown.
Group Vol. of lesions (cm3) Ratio Vol. of lesions / Vol. of
lungs (%)
Vol. of calcification (cm3) No. of animals with cavitary lesions
Mean (95% CI) Median Mean (95% CI) Median Mean (95% CI) Median
Control 49.36 (29.41–69.31) 45.73 2.48 (1.21–3.75) 2.33 10.82 (6.24–15.40) 10.03 0/6
BCG 6.20 (0–15.09) 0.53** 0.29 (0–0.72) 0.03** 2.71 (0–7.94) 0.01* 0/6
HIMB 80.80 (29.02–132.58) 80.97 4.83 (1.59–8.07) 4.31 10.41 (5.57–15.25) 9.34 3/6
*p < 0.05;
**p < 0.01;
Kruskal-Wallis test and post hoc Wilcoxon rank sum test.
https://doi.org/10.1371/journal.pone.0180546.t002
Fig 5. Individual volume of pulmonary gross lesions measured by computed tomography (CT). The figure shows rendering images of the
total lesion volume (expressed in cm3) for each lung of the 6 unvaccinated control, 6 BCG vaccinated and 6 HIMB vaccinated lambs. The trachea
and the bronchial tree are also displayed for anatomical reference.
https://doi.org/10.1371/journal.pone.0180546.g005
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were determined using histopathology. All extrapulmonary TB lesions were positive for the
presence of acid-fast bacilli by ZN stain.
Cross-sectional analysis
The association of IFN-γ responses with pathological and bacteriological parameters was eval-
uated at week 17 (10 weeks p.c. and prior to skin tests). Individual levels of IFN-γ to all anti-
gens showed statistically significant positive correlations with total volume of gross lesions and
bacterial load in LNs (Table 4).
Fig 6. Quantification of gross pathology and bacterial burden of individual lambs. Results are divided
according to treatment groups (Control, n = 6; BCG, n = 6; and HIMB, n = 6). (A) Sum of gross lesions
volumes (cm3) in lungs (measured by CT) and thoracic and retropharyngeal lymph nodes (LN, measured by
direct visual examination using a ruler). Horizontal lines indicate median values. **p < 0.01, Kruskal-Wallis
test and post hoc Wilcoxon rank sum test. (B) Total bacterial load (expressed as Log10 CFU) in whole thoracic
and retropharyngeal LNs. Horizontal lines indicate mean values. *p < 0.05, one way ANOVA and Tukey post
hoc test.
https://doi.org/10.1371/journal.pone.0180546.g006
Table 3. Extrapulmonary lesions (generalization) in non-respiratory lymph nodes (LNs).
Group Animals showing TB lesions in extrapulmonary LNs
Submandibular Retropharingeal Preescapular Hepatic Jejunal
Control 2/6 1/6 0/6 0/6 1/6
BCG 0/6 0/6 3/6 0/6 0/6
HIMB 2/6 2/6 1/6 1/6 2/6
https://doi.org/10.1371/journal.pone.0180546.t003
Table 4. Correlation of Antigen-specific IFN-γ responses at week 17 and post mortem parameters.
Antigen (IFN-γ levels as ΔOD)
PPD-B ESAT-6/CFP-10 PC-HP PC-EC
Total gross lesions (cm3) 0.5243* 0.5958** 0.6495** 0.8184***
Bacterial load (log CFU) 0.7497*** 0.7713*** 0.7052*** 0.6677**
Tabulated results are Spearman’s rho values.
*p < 0.05,
**p < 0.01,
***p < 0.001.
https://doi.org/10.1371/journal.pone.0180546.t004
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Discussion
This is the first report of an experimental model of TB in sheep. All lambs experimentally chal-
lenged by the endotracheal route with a low infective dose of M. caprae were successfully
infected and developed gross TB lesions in the respiratory system (100% infection rate). BCG
vaccine conferred considerable protection against experimental TB in lambs, as measured by a
reduction in the volume of gross lesions and bacterial load in BCG vaccinated animals. How-
ever, a single dose of HIMB vaccine did not confer any protection by the oral route at 107
CFU/ml, as neither a reduction in the volume of gross lesions nor bacterial load in respiratory
LNs were observed.
It is remarkable that all lambs subjected to experimental challenge became infected, and
implies that this study could pave the way to a reliable new experimental model for a better
understanding of TB in sheep. Sheep have traditionally been considered as less susceptible to
TB infection than other ruminants such as cattle and goats [23, 24]. Nonetheless, this study has
shown that the volume of gross pulmonary lesions, quantified by CT, and bacterial load in
respiratory LNs in lambs were similar to those observed in goats experimentally challenged
with M. caprae at a similar dose (approximately 103 CFU/ml) [21], suggesting that the suscepti-
bility of sheep to TB infection is similar to that observed in goats.
Macroscopically, lesions in all infected lambs consisted of the typical granulomatous case-
ous necrotizing lesions in the lung and associated LNs that are usually found in natural cases
of TB [5]. The presence of large necrotic coalescing lesions found in unvaccinated control
lambs indicated a fast progression of the infection to active TB, similar to what occurs in goats
[21]. In contrast, experimental infection with TB in other species such as calves and badgers
using the endobronchial route of infection did not cause large coalescent lesions [25, 26],
which might indicate a faster progression of TB in lambs compared to these species under sim-
ilar experimental conditions. Control and HIMB vaccinated lambs showed extrapulmonary
lesions in submandibular, retropharyngeal, hepatic, preescapular and mesenteric LNs indicat-
ing systemic circulation of mycobacteria, which may lead to excretion and subsequent trans-
mission by inhalatory, oral and fecal routes. Three animals of the BCG vaccinated group
showed extrapulmonary TB lesions in the right preescapular LN. This is highly suggestive of
drainage of BCG mycobacteria from the point of vaccine inoculation (right scapula) as has
been described in the goat model [14].
The efficacy of the parenterally administration of the BCG vaccine in the reduction of
clinical signs (pyrexia and prevention of weight loss), gross lesions and the incidence of pos-
itive immunological tests in lambs in this study has been also demonstrated in previous
studies in different wildlife (wild brushtail possums and badgers) and domestic (cattle and
goat) species [6, 12, 14, 27]. The efficacies of different inactivated formulations have been
tested with promising results in some cases. In cattle inactivated BCG in a mineral oil adju-
vant did not evoke protective immunity [28]. However, the subcutaneous administration of
formalin-inactivated BCG mixed with non-phospholipid liposome adjuvants in guinea pigs
conferred a significant survival advantage against lethal aerogenous challenge with M. bovis
[29]. Recent studies have also shown that orally administered heat-inactivated M. bovis vac-
cine (the same HIMB vaccine used in this study) at a similar dose (6 × 106 CFU/ml) con-
ferred protection against TB in wild boar, responding similarly to BCG [18]. The first
explanation for the failure of the HIMB vaccine to protect lambs against TB in this study
could be the route of administration. The vaccine might have been damaged in the lambs’
digestive system before being able to induce an effective immune response. The second
reason could be that lambs might require a higher dose than the one used in this experimen-
tal infection (107 CFU/ml) or even revaccination. Finally the third reason could be the
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method of challenge that by passes all the natural mucosal and lymphoid barriers over-
whelming the local immune response at the bronchial level. However, since one HIMB vac-
cinated lamb showed values in the volume of gross lesions, bacterial load and cumulative
weigh increase similar to the mean values of the BCG group, we might speculate that the
HIMB vaccine conferred protection to this animal. This may also be supported by the
slightly higher PPD-B specific IFN-γ levels of this animal detected at 7 weeks after vaccina-
tion. (ΔOD450 = 0.144) compared to the undetectable levels of the rest of the HIMB
vaccinated lambs (ΔOD450 < 0.1). Future experiments should be carried out to find the
optimal route of administration and dose of HIMB inactivated vaccine to induce protection.
The kinetics of whole blood antigen-specific IFN-γ responses is in agreement with the path-
ological and bacteriological results. The M. caprae infection induced higher IFN-γ levels either
to ESAT-6/CFP-10 or PC-EC and PC-HP peptide cocktails in unvaccinated and HIMB vacci-
nated animals compared to the BCG group, this being consistent with the vaccination outcome
assessed as volume of gross lesions and bacterial load. The association of protection with
reduced levels of systemic IFN-γ responses to growth-related mycobacterial antigens was also
observed in a number of TB vaccine trials conducted in cattle and goats [17]. All animals
responded to the DIVA-based antigen formulations (ESAT-6/CFP-10, PC-EC and PC-HP)
after challenge, whereas none of the BCG vaccinated animals responded to these antigens after
vaccination, confirming its usefulness for DIVA-based diagnosis [16, 17]. In addition, none of
the HIMB vaccinated lambs responded to DIVA antigens prior to challenge. Notwithstanding
these animals also failed to respond to PPD-B, therefore, further studies are required to assess
the suitability of these antigens as DIVA reagents for HIMB vaccination in sheep. In cattle and
deer, oral administration of HIMB also failed to generate a response against either PPD-B or
ESAT-6/CFP-10 or PC-EC and PC-HP peptide cocktails [30,31]. Post mortem parameters
were compared with IFN-γ responses at week 17 (10 weeks p.c.), once well-established the
infection, and prior to skins tests to avoid their potential interference on the IFN-γ assay. The
results elucidated that IFN-γ responses to all antigens (PPD-B, ESAT-6/CFP-10, PC-HP and
PC-EC) are immunological correlates of disease severity (i.e. gross pathology and bacterial
load). Ex vivo ESAT-6, ESAT-6-CFP-10 or PPD-B specific IFN-γ responses were previously
identified as correlates of disease severity in experimentally infected cattle and goats [17,
21, 32].
Humoral responses were measured followed by IgG ELISA to MPB83, a serodominant cell
surface protein of the MTBC that may be recognized at the early stages of the infection [33].
Interestingly, unvaccinated control lambs seroconverted earlier than lambs experimentally
infected in a previous study [21], seroconversion rates were 66% vs 9% at 4 weeks p.c. and 83%
vs 45% at 6 weeks p.c., respectively, suggesting that MTBC infection in sheep may induce a
faster humoral response to the infection. All experimental animals were seropositive at 2
weeks after SIT as a result of the PPD-boosting effect, similarly to those previously found in
cattle and goats [21, 32].
In conclusion lambs have been shown to be susceptible to M. caprae experimental infection
showing similar clinical, immunological, pathological and bacteriological parameters of infec-
tion to goats. Moreover subcutaneous BCG vaccination would offer an effective prospect for
controlling the disease in individual animals and could also reduce the prevalence of TB in
infected ovine herds. However, it is important to note that all animals became infected. This
means that, at least in this model, longer studies are needed to be sure that the short term
effects persist in the long term. Alternative doses and/or routes of administration should be
applied to evaluate the positive and/or negative effects of the HIMB vaccine candidate in this
experimental model.
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